Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of dupilumab compared with placebo on airway inflammation, airway resistance, and lung remodeling in people aged 40 to 85 years with Chronic Obstructive Pulmonary Disease COPD. This Phase 4, multinational, randomized, double-blind, placebo-controlled study aims to understand how these changes relate to lung function, exacerbations, and quality of life improvements. Participants will receive subcutaneous injections of either dupilumab or placebo following the study protocol. The treatment period lasts up to 24 weeks within a total study duration of 40 weeks, during which participants will attend nine visits. The study includes detailed lung imaging assessments to measure mucus plugging and airway changes. During the study, participants will undergo evaluations including lung mucus scoring, high-resolution CT scans, and forced oscillation technique tests to monitor airway resistance and reactance. Safety is monitored by recording adverse events up to 36 weeks. The primary outcome is the change in global lung mucus score from baseline to Week 24. Participants will be followed for the full duration to assess treatment effects and safety.
Actively Recruiting
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.